- Slowdown in clinical trial initiations; Tightening of the funding environment impacting the number of clinical trials initiated, particularly in the biotech sector; Threat of cyberattacks; Failure to attract and retain talent; IT infrastructure failures; Termination of client clinical trials; Insufficient cash reserves; Liquidity, credit, and currency risks; Failure to exploit commercial opportunities; Data protection risks.
IXICO plc
Greenhouse gas emissions & sustainability report data
In its 2024 reporting, IXICO plc disclosed greenhouse gas emissions of 555 tCO2e (Scope 3) + 5 tCO2e (Scope 1). By scope: Scope 1: 5 tCO2e; Scope 2: 0 tCO2e; Scope 3: 555 tCO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
555 tCO2e (Scope 3) + 5 tCO2e (Scope 1)
2024
Renewable Energy
100% (Scope 2)
of total energy
📊 Emissions by Scope (2024)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 5 tCO2e |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 0 tCO2e |
| Scope 3 | Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.). | 555 tCO2e |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced Scope 3 emissions by over 50% compared to 2023; Scope 2 emissions were 100% from renewable sources.
🎯 Climate & Sustainability Targets
📅 Medium-term
- Grow revenues towards £20 million+
🌱 ESG Focus Areas
Environmental ImpactPeople and SocietyResponsible Business